ArticleJMIR research protocols2025
The Malaysian Burden of Disease Study: Protocol for Mortality, Morbidity, and Risk Factor Evaluation.
Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnowledge of the burden of disease at the national level is crucial for understanding regional health patterns and epidemiological trends. Regular updates and methodological enhancements are essential to produce accurate estimates that effectively represent the current health landscape, thereby assisting policymakers in resource allocation and strategic planning.
objectiveThe objective of this study protocol is to revise the list of diseases and injuries; estimate years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) in phase 1; and identify the list of risk factors and determine risk-attributable burdens in phase 2.
methodsThe Malaysian Burden of Disease (MBOD) Study adopts the Global Burden of Disease Study approach, using various metrics to quantify health loss related to specific diseases, injuries, and risk factors. These metrics include deaths, YLLs, YLDs, and DALYs, which are calculated in terms of counts, age-specific rates, and all-age rates. In addition, this MBOD Study calculates risk-attributable deaths, YLLs, YLDs, and DALYs for all relevant risk factors. This study also conducts focus group discussions to develop the lists of diseases and injuries as well as risk factors.
resultsBy December 2024, we had successfully completed the focus group discussions, which led to the development of an updated and comprehensive list of diseases and injuries. Furthermore, mortality data collection is complete, and the calculation of YLLs is currently in progress. The YLD calculation is expected to conclude by the end of 2025. While phase 1 is underway, phase 2, which addresses risk factor estimation, is scheduled for completion in mid-2026.
conclusionsThis MBOD Study offers a comprehensive and current framework for assessing the burden of disease in Malaysia, with continuous improvement initiatives to enhance the list of diseases and injuries and refine the methodology for more accurate estimation and risk factor analysis. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/71583.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.